Ubie
Japan's leading AI symptom checker — answer 20 questions in 3 minutes, get medically vetted guidance on possible causes and next steps.
Overview
Ubie is a free AI-powered symptom checker built by doctors and engineers in Tokyo. Users answer roughly 20 adaptive questions about their symptoms in around three minutes and receive a personalised report covering likely disease candidates, recommended specialist types, and guidance on urgency — all without registration. The engine draws on 50,000+ peer-reviewed publications, covers 1,100+ conditions across 3,500 question types, and is supervised by a panel of 50+ medical specialists worldwide. An independent clinical-vignette study published on medRxiv (2024) found top-10 diagnostic accuracy of 71.6%, comparable to the median physician score of 72.9% on the same cases.
Beyond the consumer app, Ubie operates Ubie Medical Navigator — an AI patient-intake and clinical documentation platform adopted by 1,800+ Japanese hospitals and clinics — and Ubie for Pharma, a disease-awareness channel used by roughly 90% of the world's top pharmaceutical companies. The company was founded in 2017 by engineer Kota Kubo and physician Dr. Yoshinori Abe to reduce the administrative burden on doctors (interviews that took an hour can now be pre-filled in minutes). Cumulative funding exceeded $125M as of mid-2025, with strategic investors including Google, NTT Docomo, Seven-Eleven Japan, Japan Post Capital, Mizuho Financial Group, and Dai-Ichi Life Insurance.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Ubie
- Personalised symptom report listing ranked possible disease candidates within 3 minutes
- Guidance on which medical specialist to consult and estimated urgency level
- Plain-language disease information drawn from peer-reviewed publications
- Doctor's Note: written Q&A response from a medical professional (paid add-on)
- Ubie Medical Navigator: AI-generated pre-consultation intake notes for hospital staff
- Disease-awareness content channel for pharmaceutical partners (Ubie for Pharma)
- Integration with NTT Docomo d Account for personalised health guidance (Japan, 2025)
ASEAN Perspective
Ubie in Southeast Asia
Ubie opened a Singapore office in 2020 and positions it as an APAC hub, but the product's deep clinical integration — EMR links, hospital workflow tools, Japanese-language UX optimisations for elderly users — is firmly rooted in Japan. No confirmed country-specific rollouts exist for Indonesia, Malaysia, the Philippines, Thailand, or Vietnam as of mid-2026. The NTT Docomo alliance (March 2025) integrates Ubie with 100M+ Japanese d-Account holders, reinforcing Japan-first momentum. ASEAN users can access the English-language symptom checker at ubiehealth.com, but without localised disease prevalence data or regional regulatory clearances the tool's utility in Southeast Asia remains that of a general global product, not a regionally tailored one.
Ubie stands out as one of the few AI symptom checkers with published, peer-reviewed accuracy data — a 71.6% top-10 hit rate that matches median physician performance in controlled vignette studies. The consumer experience is genuinely frictionless: free, no sign-up, three minutes, mobile-friendly, and grounded in 50,000+ clinical papers rather than generic LLM output. For Japan-market healthcare stakeholders its B2B Medical Navigator suite is a serious enterprise product, trusted by nearly a third of the country's hospitals.
The caveats are meaningful. Ubie's global reach is real but skewed — Japan is its home base where it has deep clinical integration, while the US product is still scaling (4M total users vs 13M monthly globally). ASEAN coverage beyond a Singapore office is thin and not confirmed at country-level in English-language markets. There is no public API or developer platform, limiting integration for health systems outside Japan. And like all symptom checkers, results are guidance only — not diagnosis — which the product makes clear but users sometimes misread.
What people say
Ubie is one of the more clinically credible free symptom checkers, with a 2024 medRxiv study reporting top-10 accuracy close to physicians. Strong adoption signals — 10M+ monthly users and 1,800+ Japanese medical institutions (2025), plus a 2026 Mayo Clinic partnership — point to genuine traction. It is fast, registration-free and well designed. Weaknesses: no public developer API, limited ASEAN localisation beyond Singapore, and a B2B suite still largely Japan-centric. Recognised by Newsweek (2024) and Google Play (Best With AI 2023). A solid pick for personal symptom guidance; less suited to developer integration or ASEAN-specific clinical use.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Ubie's co-founder Dr. Yoshinori Abe was practising medicine when he realised doctors in Japan spend up to two hours on paperwork for every one hour with a patient — that frustration became the company's founding mission.
- An independent 2024 medRxiv study found Ubie's top-10 diagnostic accuracy (71.6%) is within one percentage point of the median physician score (72.9%) on the same clinical vignettes.
- As part of its March 2025 alliance with NTT Docomo, Ubie's symptom checker is being integrated with Docomo's 'd Account' ecosystem — giving it potential reach into over 100 million Japanese mobile subscribers.
- Ubie designed its early Japanese-market UI to resemble karaoke remote controls and ATM buttons, recognising that many elderly patients were unfamiliar with modern smartphone interfaces.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Ubie's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Ubie unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Ubie directly →
Spotted something out of date? Suggest an update →
More in Other
